Medivir AB (MVIRb.F): an All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated
5/30/2013 10:59:29 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HUDDINGE, Sweden & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.
Help employers find you! Check out all the jobs and post your resume.
comments powered by